Ascomp With Codeine Capsule
NDC Package 51991-074-01
Package Information
Ascomp With Codeine (butalbital, aspirin, caffeine and codeine phosphate) capsules is aSCOMP with Codeine is indicated for the management of the symptom complex of tension (or muscle contraction) headache, when non-opioid analgesic and alternative treatments are inadequate.Limitations of Use:Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.1)], reserve opioid analgesics, including ASCOMP with Codeine, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.ASCOMP with Codeine should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. This formulation utilizes a capsule delivery system. Marketed by Breckenridge Pharmaceutical, Inc., this product is identified by NDC 51991-074 and is authorized under FDA application ANDA075231.
Identification & Billing
- RxCUI: 994237 - butalbital 50 MG / aspirin 325 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule
- RxCUI: 994237 - aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule
- RxCUI: 994237 - ASA 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule
- RxCUI: 994239 - Ascomp with Codeine 50 MG / 325 MG / 40 MG / 30 MG Oral Capsule
- RxCUI: 994239 - aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp]
Clinical Specifications
- Anti-Inflammatory Agents, Non-Steroidal - [CS]
- Barbiturate - [EPC] (Established Pharmacologic Class)
- Barbiturates - [CS]
- Central Nervous System Stimulant - [EPC] (Established Pharmacologic Class)
- Central Nervous System Stimulation - [PE] (Physiologic Effect)
- Cyclooxygenase Inhibitors - [MoA] (Mechanism of Action)
- Decreased Platelet Aggregation - [PE] (Physiologic Effect)
- Decreased Prostaglandin Production - [PE] (Physiologic Effect)
- Full Opioid Agonists - [MoA] (Mechanism of Action)
- Methylxanthine - [EPC] (Established Pharmacologic Class)
- Nonsteroidal Anti-inflammatory Drug - [EPC] (Established Pharmacologic Class)
- Opioid Agonist - [EPC] (Established Pharmacologic Class)
- Platelet Aggregation Inhibitor - [EPC] (Established Pharmacologic Class)
- Xanthines - [CS]
Regulatory & Marketing
Hierarchy Structure
- 51991 - Breckenridge Pharmaceutical, Inc.
- 51991-074 - Ascomp With Codeine
- 51991-074-01 - 100 CAPSULE in 1 BOTTLE, PLASTIC
- 51991-074 - Ascomp With Codeine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (51991-074). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51991-074-01 identifies a specific commercial package of 100 capsule in 1 bottle, plastic of Ascomp With Codeine, a human prescription drug labeled by Breckenridge Pharmaceutical, Inc.. This capsule is formulated for oral use and contains butalbital; aspirin; caffeine; codeine phosphate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Breckenridge Pharmaceutical, Inc. on May 01, 2009. The current certification is valid through December 31, 2027.
How is this Breckenridge Pharmaceutical, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51991007401. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.